IOVA earnings: a positive outcome, +5.2%

On February 24, 2022, Iovance Biotherapeutics, Inc. reached its earnings. The result was a positive outcome, and the stock moved +5.2% in the window around the event. It had already run +9.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.